Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 35170072.
- Also identified by DOI 10.1002/ana.26328 and PMC identifier 9314128.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment with dimethyl fumarate (DMF) leads to lymphopenia and infectious complications in a subset of patients with multiple sclerosis (MS). Here, we aimed to reveal immune markers of DMF-associated lymphopenia. This prospective observational study longitudinally assessed 31 individuals with MS by single-cell mass cytometry before and after 12 and 48 weeks of DMF therapy. Employing a neural network-based representation learning approach, we identified a CCR4-expressing T helper cell population negatively associated with relevant lymphopenia. CCR4-expressing T helper cells represent a candidate prognostic biomarker for the development of relevant lymphopenia in patients undergoing DMF treatment. ANN NEUROL 2022;91:676-681.
Medical subject headings
- Lymphopenia
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting